Medical Treatment of Echinococcus multilocularis and New Horizons for Drug Discovery: Characterization of Mitochondrial Complex II as a Potential Drug Target
Authors:
- Shigehiro EnkaiSEShigehiro Enkai
- Kimitoshi SakamotoKSKimitoshi Sakamoto
- Miho KanekoMKMiho Kaneko
- Hirokazu KouguchiHKHirokazu Kouguchi
- Takao IrieTITakao Irie
- Kinpei YagiKYKinpei Yagi
- Yuka IshidaYIYuka Ishida
- Jun MatsumotoJMJun Matsumoto
- Yuzaburo OkuYOYuzaburo Oku
- Ken KatakuraKKKen Katakura
- Osamu FujitaOFOsamu Fujita
- Tomoyoshi NozakiTNTomoyoshi Nozaki
Open Access
- 15 November 2017
- book chapter
- Published by IntechOpen
Abstract
As an efficient drug for alveolar echinococcosis (AE) is still not available, new chemotherapy targets are necessary. The mitochondrial respiratory chain may be a good drug candidate because parasite respiratory chains are quite different from those of mammalian hosts. For example, Ascaris suum possesses an NADH‐fumarate reductase system (fumarate respiration) that is highly adapted to anaerobic environments such as the small intestine. It is composed of mitochondrial complex I (NADH‐ubiquinone reductase), complex II (succinate‐ubiquinone reductase), and rhodoquinone. We previously demonstrated that fumarate respiration is also essential in E. multilocularis. Quinazoline, a complex I inhibitor, inhibited growth of E. multilocularis larvae in vitro. These results indicate that fumarate respiration could be a target for E. multilocularis therapy. In the current chapter, we focused on complex II, which is another component of this system, because quinazoline exhibited strong toxicity to mammalian mitochondria. We evaluated the molecular and biochemical characterization of E. multilocularis complex II as a potential drug target. In addition, we found that ascofuranone, a trypanosome cyanide‐insensitive alternative oxidase inhibitor, inhibited E. multilocularis complex II at the nanomolar order. Our findings demonstrate the potential development of targeted therapy against Echinococcus complex II.Keywords
This publication has 53 references indexed in Scilit:
- Characterization of a Surface Glycoprotein from Echinococcus multilocularis and Its Mucosal Vaccine Potential in DogsPLOS ONE, 2013
- Bioinformatic prediction of epitopes in the Emy162 antigen of Echinococcus multilocularisExperimental and Therapeutic Medicine, 2013
- Diversity of parasite complex IIBiochimica et Biophysica Acta (BBA) - Bioenergetics, 2013
- The genomes of four tapeworm species reveal adaptations to parasitismNature, 2013
- A Pilot Study on Developing Mucosal Vaccine against Alveolar Echinococcosis (AE) Using Recombinant Tetraspanin 3: Vaccine Efficacy and ImmunologyPLOS Neglected Tropical Diseases, 2012
- SDH5 , a Gene Required for Flavination of Succinate Dehydrogenase, Is Mutated in ParagangliomaScience, 2009
- Crystallization of mitochondrial rhodoquinol-fumarate reductase from the parasitic nematodeAscaris suumwith the specific inhibitor flutolanilActa Crystallographica Section F Structural Biology and Crystallization Communications, 2009
- The translocator maintenance protein Tam41 is required for mitochondrial cardiolipin biosynthesisJournal of Cell Biology, 2008
- An Oral Recombinant Vaccine in Dogs against Echinococcus granulosus, the Causative Agent of Human Hydatid Disease: A Pilot StudyPLOS Neglected Tropical Diseases, 2008
- The vaccination potential of EMY162 antigen against Echinococcus multilocularis infectionBiochemical and Biophysical Research Communications, 2007